(Q46639990)

23 December 2017

title

Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial (English)

1 reference

23 December 2017

multicenter clinical trial

1 reference

1 reference

0 references

1

1 reference

23 December 2017

Xavier Calvet

2

1 reference

23 December 2017

Luis Bujanda

4

1 reference

23 December 2017

Javier P Gisbert

7

1 reference

23 December 2017

author name string

J Ducons

3

1 reference

23 December 2017

F Bory

5

1 reference

23 December 2017

A Montserrat

6

1 reference

23 December 2017

Hp Study Group of the Asociación Española de Gastroenterología

8

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

23 December 2017

The American Journal of Gastroenterology

published in

1 reference

23 December 2017

volume

100

1 reference

23 December 2017

page(s)

1696-1701

1 reference

23 December 2017

issue

8

1 reference

23 December 2017

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Helicobacter pylori-related disease: guidelines for testing and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Seven-day therapy for Helicobacter pylori in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Helicobacter pylori public health implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Screening for gastric cancer: does it make sense?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Are there geographical and regional differences in Helicobacter pylori eradication?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Relevance of underlying disease and bacterial vacA and cagA status on the efficacy of Helicobacter pylori eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Factors affecting the variation in antibiotic resistance of Helicobacter pylori over a 3-year period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Evolution of the sensitivity of 235 strains of Helicobacter pylori from 1995 to 1998 and impact of antibiotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Rifabutin-based Helicobacter pylori eradication 'rescue therapy'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

High eradication rates of Helicobacter pylori with a new sequential treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.50019.X

10.1111/J.1572-0241.2005.50019.X

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

16086704

1 reference

23 December 2017